Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alfuzosin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D known ✓ | P25100 | 3/20 | 0.97 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.97 |
| ▸ | ADRA1B known ✓ | P35368 | 3/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.97 |
| ▸ | GLA | P06280 | 5/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.97 |
| ▸ | HPGD | P15428 | 5/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.97 |
| ▸ | GAA | P10253 | 4/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.97 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.97 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.97 |
| ▸ | ACHE | P22303 | 1/20 | 0.97 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.97 |
| ▸ | DRD3 | P35462 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alfuzosin SCHEMBL8115183 | 1.00 | KDM4E (0.97) | KDM4EGLAALDH1A1HPGDHSD17B10 | |
| Alfuzosin SCHEMBL8108037 | 1.00 | KDM4E (0.97) | KDM4EGLAALDH1A1HPGDHSD17B10 | |
| Alfuzosin SCHEMBL30690015 | 0.99 | KDM4E (0.98) | KDM4EGLAALDH1A1HPGDHSD17B10 | |
| Alfuzosin SCHEMBL4745192 | 0.99 | KDM4E (0.98) | KDM4EGLAALDH1A1HPGDHSD17B10 | |
| Alfuzosin SCHEMBL179910 | 0.99 | KDM4E (0.98) | KDM4EGLAALDH1A1HPGDHSD17B10 | |
| Alfuzosin SCHEMBL4744369 | 0.99 | KDM4E (0.98) | KDM4EGLAALDH1A1HPGDHSD17B10 | |
| Alfuzosin SCHEMBL2851348 | 0.99 | KDM4E (0.98) | KDM4EGLAALDH1A1HPGDHSD17B10 | |
| Alfuzosin SCHEMBL29492949 | 0.99 | KDM4E (0.98) | KDM4EGLAALDH1A1HPGDHSD17B10 | |
| Alfuzosin SCHEMBL1690827 | 0.98 | KDM4E (0.97) | KDM4EGLAALDH1A1HPGDHSD17B10 | |
| Alfuzosin SCHEMBL34477 | 0.98 | KDM4E (1.00) | KDM4EGLAALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110354131-A | Alfuzosin is treating or preventing the purposes in Parkinson's disease and related disease | 刘磊 | 2019-10-22 | — | — | CN | claimed |
| EP-0663398-B1 | Dihydrate of N-(4-amino-6,7-dimethoxyquinazol-2-yl)-N-methyl-N'-(tetrahydrofuroyl-2)-propylene diamine hydrochloride (= alfuzosin hydrochloride dihydrate) and a process for the preparation | SANOFI SYNTHELABO (FR) | 2000-03-15 | — | — | EP | claimed |
| US-5545738-A | USEFUL FOR PRODUCTION OF ANTIHYPERTENSIVE AGENTS AND DYSUREA CURING AGENTS | SYNTHELABO (FR) | 1996-08-13 | — | — | US | claimed |
| EP-0663398-A1 | Dihydrate of N-(4-amino-6,7-dimethoxyquinazol-2-yl)-N-methyl-N'-(tetrahydrofuroyl-2)-propylene diamine hydrochloride (= alfuzosin hydrochloride dihydrate) and a process for the preparation | SYNTHELABO (FR) | 1995-07-19 | — | — | EP | claimed |
| CN-111035642-A | Application of alfuzosin compound in preventing or treating Alzheimer's disease and related diseases | 山东邦恩泰生物医药科技集团有限公司 | 2020-04-21 | — | — | CN | disclosed |
| CN-110354131-A | Alfuzosin is treating or preventing the purposes in Parkinson's disease and related disease | 刘磊 | 2019-10-22 | — | — | CN | disclosed |
| US-8093384-B2 | Processes for the preparation of alfuzosin | WOCKHARDT LTD. (IN) | 2012-01-10 | — | — | US | disclosed |
| US-20100174073-A1 | PROCESS FOR THE PREPARATION OF ALFUZOSIN AND SALTS THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2010-07-08 | — | — | US | disclosed |
| EP-2152697-A2 | PROCESS FOR THE PREPARATION OF ALFUZOSIN AND SALTS THEREOF | Actavis Group PTC EHF (IS) | 2010-02-17 | — | — | EP | disclosed |
| WO-2010010058-A1 | METHOD OF PREPARING ANHYDROUS ALFUSOZIN HYDROCHLORIDE | LUNDBECK PHARMACEUTICALS ITALY S.P.A. (IT) | 2010-01-28 | — | — | WO | disclosed |
| US-20090312351-A1 | Processes for the Preparation of Alfuzosin | NATHANI PANKAJ KUMAR | 2009-12-17 | — | — | US | disclosed |
| WO-2008152514-A2 | PROCESS FOR THE PREPARATION OF ALFUZOSIN AND SALTS THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2008-12-18 | — | — | WO | disclosed |
| EP-0663398-B1 | Dihydrate of N-(4-amino-6,7-dimethoxyquinazol-2-yl)-N-methyl-N'-(tetrahydrofuroyl-2)-propylene diamine hydrochloride (= alfuzosin hydrochloride dihydrate) and a process for the preparation | SANOFI SYNTHELABO (FR) | 2000-03-15 | — | — | EP | disclosed |
| EP-0663398-B1 | Dihydrate of N-(4-amino-6,7-dimethoxyquinazol-2-yl)-N-methyl-N'-(tetrahydrofuroyl-2)-propylene diamine hydrochloride (= alfuzosin hydrochloride dihydrate) and a process for the preparation | SANOFI SYNTHELABO (FR) | 2000-03-15 | — | — | EP | disclosed |
| US-5545738-A | USEFUL FOR PRODUCTION OF ANTIHYPERTENSIVE AGENTS AND DYSUREA CURING AGENTS | SYNTHELABO (FR) | 1996-08-13 | — | — | US | disclosed |
| US-5545738-A | USEFUL FOR PRODUCTION OF ANTIHYPERTENSIVE AGENTS AND DYSUREA CURING AGENTS | SYNTHELABO (FR) | 1996-08-13 | — | — | US | disclosed |
| US-5545738-A | USEFUL FOR PRODUCTION OF ANTIHYPERTENSIVE AGENTS AND DYSUREA CURING AGENTS | SYNTHELABO (FR) | 1996-08-13 | — | — | US | disclosed |
| EP-0663398-A1 | Dihydrate of N-(4-amino-6,7-dimethoxyquinazol-2-yl)-N-methyl-N'-(tetrahydrofuroyl-2)-propylene diamine hydrochloride (= alfuzosin hydrochloride dihydrate) and a process for the preparation | SYNTHELABO (FR) | 1995-07-19 | — | — | EP | disclosed |
| EP-0663398-A1 | Dihydrate of N-(4-amino-6,7-dimethoxyquinazol-2-yl)-N-methyl-N'-(tetrahydrofuroyl-2)-propylene diamine hydrochloride (= alfuzosin hydrochloride dihydrate) and a process for the preparation | SYNTHELABO (FR) | 1995-07-19 | — | — | EP | disclosed |
| EP-0663398-A1 | Dihydrate of N-(4-amino-6,7-dimethoxyquinazol-2-yl)-N-methyl-N'-(tetrahydrofuroyl-2)-propylene diamine hydrochloride (= alfuzosin hydrochloride dihydrate) and a process for the preparation | SYNTHELABO (FR) | 1995-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100174073-A1 | PROCESS FOR THE PREPARATION OF ALFUZOSIN AND SALTS THEREOF | AADAC, PTMS, LPXN | ADRA1D 77/4885ADRA1A 54/4885ADRA1B 117/4885 |
| US-20090312351-A1 | Processes for the Preparation of Alfuzosin | LPXN, EPM2A, PSAP | ADRA1D 55/4885ADRA1A 47/4885ADRA1B 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.